Physician profile
Michael E Hill
NPI 1104168327
$2,846.81
in general payments reported to CMS, 2019-2025
21 companies · $633 in 2025
The $633 reported for 2025 was more than what 79% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $542 · 2022: $402 · 2023: $674 · 2024: $595 · 2025: $633.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,902.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,902.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $640.60 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $508.25 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals Lp | $502.83 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Abbvie INC. | $475.43 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $146.26 | 2021-2024 | |
| Novo Nordisk INC | $133.87 | 2021-2025 | Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $82.80 | 2021-2024 | Tradjenta, Jardiance, Synjardy |
| Mylan Specialty L.P. | $61.39 | 2021-2023 | Yupelri |
| Pfizer INC. | $44.97 | 2021 | |
| Exact Sciences Corporation | $39.25 | 2024 | Cologuard Collection Kit |
| Amarin Pharma, INC. | $34.76 | 2021 | |
| Ardelyx, INC. | $21.97 | 2025 | Ibsrela |
| Viatris Specialty LLC | $20.89 | 2025 | Yupelri |
| Biohaven Pharmaceutical Holding Company Ltd. | $20.43 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.35 | 2024 | Xifaxan |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intra-Sana Laboratories | $18.87 | 2024 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
| Amgen INC. | $18.46 | 2023 | Repatha |
| Vanda Pharmaceuticals INC. | $18.06 | 2024 | Fanapt, Hetlioz |
| Dexcom, INC. | $14.16 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $12.83 | 2021 | |
| Inogen, INC. | $10.38 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Hill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.